← All trials

NCT05073458

Phase 3Interventional

Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.

View on ClinicalTrials.gov ↗

Timeline

Start date
Nov 12, 2021
Primary completion
Mar 13, 2024
Completion date
Jun 4, 2024
First posted
Oct 11, 2021
Last posted
Oct 14, 2021
Enrollment
100
Arms / groups
2 / —
Source
AACT · ingestion pipeline

Sponsors

Drugs studied

Indications studied

CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.